These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 9197032)
1. [Emergency of fluconazole-resistant infections by Candida krusei and Candida glabrata in neutropenic patients]. Piemonte P; Conte G; Flores C; Barahona O; Araos D; Alfaro J; Fardella P; Thompson L Rev Med Chil; 1996 Sep; 124(9):1149. PubMed ID: 9197032 [No Abstract] [Full Text] [Related]
2. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648 [TBL] [Abstract][Full Text] [Related]
3. Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients. Bussaratid V; Tansupasawasdikul S; Simpson A; Pitisuttithum P; Phonrat B; Howe P; White NJ J Med Assoc Thai; 2002 Jul; 85(7):757-64. PubMed ID: 12296406 [TBL] [Abstract][Full Text] [Related]
4. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304 [TBL] [Abstract][Full Text] [Related]
5. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153 [TBL] [Abstract][Full Text] [Related]
6. Current treatment strategies for disseminated candidiasis. Spellberg BJ; Filler SG; Edwards JE Clin Infect Dis; 2006 Jan; 42(2):244-51. PubMed ID: 16355336 [TBL] [Abstract][Full Text] [Related]
7. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778 [TBL] [Abstract][Full Text] [Related]
9. [Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies]. Rimek D; Redetzke K; Kappe R Mycoses; 2006; 49 Suppl 2():18-23. PubMed ID: 17022757 [TBL] [Abstract][Full Text] [Related]
10. Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? Drew RH Ann Pharmacother; 2007 Apr; 41(4):690-2. PubMed ID: 17389669 [TBL] [Abstract][Full Text] [Related]
11. Candiduria in hospitalized patients: a review. Nucci M Braz J Infect Dis; 2000 Aug; 4(4):168-72. PubMed ID: 11008220 [TBL] [Abstract][Full Text] [Related]
12. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia. Wilson AG; Micek ST; Ritchie DJ Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247 [TBL] [Abstract][Full Text] [Related]
13. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia. Myoken Y; Kyo T; Kohara T; Fujihara M; Sugata T; Mikami Y Clin Infect Dis; 2003 Jun; 36(11):1496-7. PubMed ID: 12766847 [No Abstract] [Full Text] [Related]